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Introduction
Globally, lung cancer accounts for 12% (2.1 million) of new 
cancer cases and 18% (1.8 million) of cancer-related deaths 
based on the global cancer statistics of 2018 [1]. In both 
genders, lung cancer is the most commonly diagnosed cancer 
and the most common cause of cancer death. In Korea, lung 
cancer was the fourth most commonly diagnosed cancer 
(26,000) and the leading cause (18,000) of cancer death in 
2016 [2]. The 5-year relative survival rate of lung cancer 
between 2012 and 2016 was 28% in Korea. Platinum-based 
doublet chemotherapy has been the standard treatment 
for metastatic non-small cell lung cancer (NSCLC), but it 
leads to poor outcomes with a median survival of 8–11 
months [3,4]. Thus, the role of radiotherapy for advanced 
lung cancer has been limited to palliative treatment to 
alleviate patients’ symptoms. However, the development 
of advanced radiotherapy techniques and recent advances 
In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the 
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that can achieve long-term survival from aggressive local management. There is no consensus on the definition of oligometastasis; 
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have shown that ablative RT, including stereotactic ablative body radiotherapy (SABR) and hypofractionated RT, to primary and 
metastatic sites improved progression-free survival (PFS) and overall survival (OS) in patients with oligometastatic NSCLC. The 
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in pharmacotherapy, including cytotoxic chemotherapy, 
molecular-targeted therapy, and immune checkpoint blockade, 
have resulted in a growing interest for local ablative therapy 
(LAT) for oligometastatic diseases. Currently, there is no 
consensus on the definition of oligometastasis. However, most 
studies defined oligometastatic disease as having 1–3 or 1–5 
metastatic lesions [5-8]. In this review, we will briefly describe 
the biological and clinical rationales of LAT for oligometastasis 
and summarize the recent prospective clinical trials on LAT for 
oligometastatic NSCLC.
Biological Rationale of LAT for 
Oligometastasis
Recent next-generation sequencing (NGS) technology allows 
the phylogenetic analysis of primary and metastatic tumors 
and reveals branched evolutionary tumor progression [9-
11]. Genomic analysis in patients with NSCLC has shown that 
primary tumors and lung metastasis share a common driver 
mutation [12,13]. These data indicate that primary tumor and 
its metastases are clonally related, and they originate from a 
common ancestral cell. Phylogenetic trees or relationships of 
primary and metastatic subclones can be estimated by analysis 
of ubiquitous, shared, and private mutations. According to the 
relative timing of the emergence of new metastatic subclones 
and degree of genetic divergence between primary and 
metastatic tumors, models of metastatic evolution or cascade 
can be classified into linear and parallel progression models 
[14-16]. Early emergence of metastatic subclones and high 
degree of genetic divergence favor the parallel progression 
model of metastatic cascade, while late emergence of 
metastatic subclones and low degree of genetic divergence 
support the linear progression model [16,17] (Fig. 1). In the 
linear progression model, metastasis can occur late during 
disease progression; however, in the parallel progression model, 
early dissemination of tumor cells can occur. In both linear 
and parallel progression models, intratumoral heterogeneity of 
the primary tumor and earlier metastasis can lead to further 
disseminated metastases. As a result, LAT to the primary tumor 
and early metastatic lesions may prevent emergence of new 
metastasis-competent clone and progression to disseminated 
metastasis. Therefore, improving survival by performing LAT at 
the limited metastatic stage is possible in the two progression 
models of metastatic evolution.
Radiotherapy Techniques
LAT options for patients with limited metastasis include 
surgical resection, radiotherapy, radiofrequency ablation, 
and cryoablation [18-22]. Radiotherapy is a nonsurgical and 
noninvasive treatment, and high-dose radiation shows good 
tumor control. Stereotactic ablative radiotherapy (SABR), 
also known as stereotactic body radiotherapy, refers to 
stereotactically guided delivery of highly conformal radiation 
with ablative dose in a limited number of fractions [23]. 
SABR for metastatic lesions in various sites, including the 
lung, liver, adrenal gland, lymph nodes, and spine, has shown 
good local control rates ranging from 70% to 100% and 
acceptable treatment-related toxicities [24-30]. Typically, 
noninvasive positioning techniques, such as those in image-
guided radiotherapy, and short treatment courses with 1, 3, 
or 5 fractions are used. The ongoing randomized phase II/III 
trial (NRG-LU002) comparing local consolidative therapy and 
maintenance systemic therapy for limited metastatic NSCLC 
uses radiation doses of 24 Gy (acceptable variation, 21–27 Gy) 
with 1 fraction, 30 Gy with 3 fractions (acceptable variation, 
26.5–33 Gy), and 34 Gy with 5 fractions (acceptable variation, 
30–37.5 Gy) for SABR. For the primary site, 45 Gy (acceptable 
variation, 42–48 Gy) with 15 fractions is used.
Interestingly, a recent systematic study analyzed the effects 
of the types of LAT on OS in oligometastatic NSCLC patients 
[31]. According to this study, the use of SABR instead of 
conventionally fractionated radiotherapy for these patients 
rapidly increased after 2011, and a time trend towards 
improved OS after 2011 was detected. Moreover, the types 
of LAT including radiotherapy and surgery for primary tumor 
or distant metastasis did not result in a significant effect on 
median OS.
Fig. 1. Intratumoral heterogeneity and genetic differences in the 
linear and parallel progression models.
RT for oligometastatic lung cancer
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1. Radiotherapy for oligometastatic NSCLC
The Stereotactic Ablative Radiotherapy for the Comprehensive 
Treatment of Oligometastasis (SABR-COMET) study, a 
randomized phase II trial, demonstrated that the addition of 
SABR to all sites of disease improved the overall survival (OS) 
and progression-free survival (PFS) in patients with controlled 
primary tumor and up to 5 metastatic lesions [32]. In this 
study, 99 patients with breast, prostate, and lung cancers 
were randomized to receive standard of care with palliative 
treatments (control group) or standard of care with SABR to 
all sites of metastatic disease (SABR group) in a 1:2 ratio. The 
use of SABR resulted in a 13-month improvement in the OS 
(median OS, 28 months vs. 41 months) with a doubling of 
PFS (median PFS, 6 months vs. 12 months). The frequencies 
of adverse events ≥grade 2 were 9% and 29% in the control 
and SABR groups, respectively. Another randomized phase II 
trial also showed the survival benefit of local radiotherapy 
for stage IV NSCLC with ≤3 metastatic lesions [7]. After first-
line systemic therapy, 49 patients without disease progression 
were randomly assigned to receive local consolidative therapy 
to all known disease sites including primary and lymph nodes 
or maintenance treatment in a 1:1 ratio. Local consolidate 
therapy consisted of SABR, intermediately hypofractionated 
radiotherapy (15 fractions to the mediastinum), and 
concurrent chemoradiotherapy, and surgery to all sites or 
combined with radiotherapy. The long-term results of this 
study also confirmed that local consolidative therapy improved 
the OS (median OS, 17 months vs. 41 months) and PFS (median 
PFS, 6 months vs. 12 months) [33]. 
2. Radiotherapy for patients with epidermal growth 
factor receptor mutation
Epidermal growth factor receptor-tyrosine kinase inhibitor 
(EGFR-TKI) treatment improves OS in advanced NSCLC with 
EGFR mutation compared with standard first-line systemic 
treatment with a platinum-based doublet regimen [4]. This 
landmark study has changed clinical practices in patients 
with advanced NSCLC. Presently, molecular biology tests are 
essential in determining a treatment strategy, and EGFR-TKI is 
the first-line treatment for patients with activating mutations 
[34]. However, drug resistance and disease progression are 
inevitable during first- and second-generation EGFR-TKI 
treatments. Several phase III studies have shown a median PFS 
of 9–13 months with EGFR-TKI treatments [35-37]. Although 
third-generation EGFR-TKI targeting the EGFR p.Thr790Met 
point mutation (T790M) shows superior PFS than standard 
EGFR-TKIs only targeting exon 19 deletion and exon 21 L858R 
point mutation [38], drug-resistant mutations eventually 
develop in approximately 40% of patients [39,40]. When 
acquired resistance developed, local progression occurred in 
approximately one-fourth of patients, and LAT was suitable 
in approximately half of patients [41]. Therefore, LAT can be 
reasonable for patients with oligoprogression during EGFR-TKI 
treatment. 
Xu et al. [42] retrospectively analyzed the survival benefit 
of LAT in patients with stage IV EGFR-mutant NSCLC who 
have oligometastatic disease with ≤5 metastatic lesions. In 
this study, after first-line EGFR TKI treatment, 51 patients 
received LAT for both primary tumor and all metastatic sites 
(all-LAT group), 55 patients received LAT for either primary 
tumor or metastatic sites (part-LAT group), and 39 patients 
did not receive LAT (non-LAT group). The all-LAT group shows 
significantly better PFS than the part-LAT group (hazard ratio 
[HR] = 0.47) and non-LAT group (HR = 0.32). The median OS 
of the all-LAT group (41 months) was also better than those 
in the part-LAT group (34 months) and non-LAT group (HR = 
0.32). However, between the part-LAT and non-LAT groups, 
differences in the PFS and OS were not significant. In the 
multivariate analysis, exon 19 deletion (vs. exon 21 L858R 
point mutation), single metastasis (vs. multiple metastasis), 
and LAT for primary tumor (vs. no LAT for primary tumor) were 
associated with better OS. These results indicate that LAT for all 
metastatic sites as well as primary tumor may be paramount 
in improving OS.
A single-arm phase II study (NCT01941654) investigated the 
effects of preemptive LAT to residual oligometastasis (ATOM) 
in patients with advanced NSCLC with exon 19 deletion or 
L858R point mutation. After 3 months of first-line EGFR-
TKI treatment, when ≤4 positron emission tomography-avid 
lesions persisted, LAT by either SABR or surgery was performed 
and EGFR-TKI treatment was continued after LAT. In this 
prospective study, 18 patients were enrolled, and 16 patients 
showed promising PFS (1-year PFS rate post-LAT, 63%).
These data indicate that LAT can be an attractive option for 
patients with oligopersistent or oligoprogressive disease during 
EGFR-TKI treatment. Pan-Asian-adapted clinical practice 
guidelines recommend LAT in patients with oligoprogression 
after first-line EGFR-TKI treatment [34].
3. Radiotherapy with immune checkpoint blockade
In patients with lung adenocarcinoma, approximately one-
fifth to one-third patients have EGFR mutation, echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma 
kinase (ALK) fusion, or c-ros oncogene 1 fusion [43-45]. They 
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are good candidates for targeted therapy, including EGFR-
TKI and ALK inhibitor treatment. However, in patients with 
lung squamous cell carcinoma, the rate of EGFR mutation 
is extremely low [46,47]. Therefore, treatment options for 
patients with lung squamous cell carcinoma are limited to 
cytotoxic agents.
Costimulatory molecules of T cells, including programmed 
death ligand 1 (PD-L1), programmed death 1 (PD-1), and 
cytotoxic T-lymphocyte-associated antigen 4, induce T-cell 
exhaustion and contribute to the escape of tumor cells from 
host immune surveillance [48]. Recent clinical trials have 
demonstrated that compared with conventional cytotoxic 
chemotherapy in patients with advanced or previously treated 
NSCLC, including squamous cell carcinoma, immune checkpoint 
blockades inhibiting suppressive costimulatory molecules of T 
cells improved OS [49-53]. The randomized phase III PACIFIC 
trial showed that compared to placebo therapy, adjuvant 
durvalumab treatment blocking the interaction of PD-1 with 
PD-L1 after concurrent chemoradiation for stage 3 NSCLC 
improved OS [54]. As a result, the role of radiotherapy in 
immuno-oncology has emerged.
A recent single-arm phase II study evaluated LAT combined 
with pembrolizumab treatment targeting PD-1 in patients with 
NSCLC with ≤4 metastatic lesions [55]. After performing LAT 
to all known sites of disease, pembrolizumab was administered 
for 6 months and continued to 12 months in the absence of 
disease progression or untoward toxic effects. A combination 
of LAT and pembrolizumab treatment resulted in promising 
outcomes with a 2-year OS rate of 77.5% and a median PFS 
of 18.7 months. A randomized phase II PEMBRO-RT trial also 
showed the benefit of SABR combined with pembrolizumab 
treatment [56]. Previously treated patients with NSCLC were 
randomly assigned to SABR plus pembrolizumab arm or 
pembrolizumab alone arm. SABR, which consisted of 24 Gy 
in 3 fractions, was performed in a single tumor site within 7 
days prior to the first cycle of pembrolizumab treatment. SABR 
prior to pembrolizumab treatment significantly improved the 
overall response rate compared with pembrolizumab treatment 
alone (36% vs. 18%). The addition of SABR showed a tendency 
towards better PFS and OS than pembrolizumab treatment 
alone, although these results did not reach statistical 
significance. Interestingly, in the subgroup analyses, the largest 
benefit from the addition of SABR was observed in patients 
with PD-L1-negative tumors.
Ongoing Clinical Trials
Although several prospective trials have demonstrated the 
survival benefit of ablative radiotherapy for oligometastatic 
NSCLC, these were phase II studies and enrolled a small number 
of patients (Table 1). Presently, several ongoing phase III trials 
analyze the effects of ablative radiotherapy for oligometastatic 
NSCLC. The phase II/III trial in the UK (NCT02759783) compares 
conventional care versus radioablation for extracranial 
oligometastasis (CORE) in patients with prostate cancer, 
breast cancer, and NSCLC. The SARON trial (NCT02417662) is 
a randomized and multicenter phase III trial that is assessing 
the addition of SABR and radical radiotherapy to standard 
chemotherapy for oligometastatic NSCLC [57]. The SABR-
COMET 3 (NCT03862911) is a phase III randomized trial and 
will evaluate the survival benefit of the addition of SABR 
to standard systemic treatments in oligometastatic cancer 
with 1–3 metastatic lesions. The SABR-COMET 10 phase III 
randomized trial (NCT03721341) also assesses the addition of 
SABR in patients with 1–10 metastatic lesions. The NRG-LU002 
trial is a phase II/III trial that evaluates the addition of SABR or 
hypofractionated radiotherapy for all disease sites to standard 
systemic therapy. These phase III trials are expected to confirm 
the role of SABR or ablative radiotherapy in oligometastatic 
NSCLC.
Future Perspectives
Despite the abundant clinical and biological evidences that 
support the need for LAT for oligometastatic diseases, there 
are inadequate relevant biological markers predicting the 
prognosis of oligometastatic diseases and treatment response 
of LAT. To maximize the benefit of LAT, novel biomarkers 
for proper patient selection should be defined. Moreover, 
with the advances of immune checkpoint blockades and 
targeted agents, the optimum combination of LAT and these 
drugs should be investigated. Additionally, for better LAT, a 
comparison of SABR and minimally invasive surgery in future 
prospective trials is needed.
Conclusion
Recent phase II trials have shown that LAT in patients with 
lung cancer and limited metastatic diseases improved PFS 
and OS. The combination of SABR to metastatic lesions 
and hypofractionated radiotherapy to the primary site with 
standard systemic treatments seems to produce paramount 
treatment outcomes. Moreover, LAT demonstrated reasonable 
outcomes when combined with EGFR-TKI or immune 
RT for oligometastatic lung cancer
153www.e-roj.orghttps://doi.org/10.3857/roj.2019.00514
checkpoint inhibitor treatment. With the development of 
novel biomarkers, targeted therapies, and immuno-oncologic 
agents, LAT, including SABR and ablative hypofractionated 
radiotherapy, will be an attractive new treatment strategy for 
oligometastatic NSCLC in the near future.
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